SignalGeneriX Advances Early-Stage Research on Innovative Endometriosis Detection Technologies – Signalgenerix
News > 2024 > SignalGeneriX Advances Early-Stage Research on Innovative Endometriosis Detection Technologies

SignalGeneriX Advances Early-Stage Research on Innovative Endometriosis Detection Technologies

Share

SignalGeneriX plays a vital role in the European project SENSOPAD, which has a funding of 7 million euros by the Horizon Europe program.

SENSOPAD, coordinated by the National Technical University of Athens, consists of the development of advanced sensors that will be integrated into portable self-monitoring devices for the detection of relevant biomarkers.

SENSOPAD could revolutionise the way we address endometriosis. This project represents an advancement in early diagnosis and monitoring of endometriosis since for over 40 years nothing has been developed. The project involves the design and development of two distinct endometriosis detection systems: the sensoPAD and the sensoMFgFET device, which use cutting-edge technology to provide timely information that helps in the prognosis of endometriosis.

At first, sensoPAD will be used to detect and quantify pro-inflammatory and anti-inflammatory proteins, since it will be located in a conductive layer in a sanitary napkin. Therefore, sensoPAD will allow self-monitoring of early presence of endometriosis during the menstrual cycle. If a possible endometriosis is detected, then portable microdevice sensoMFgFET – Microfluidic graphene Field Effect Transistor can be used after attending a clinic. SensoMFgFET has the ability to detect specific genetic single-nucleotide polymorphisms (SNPs) from menstrual fluid, that act as early indicators of the disease. Both sensoPAD and sensoMFgFET transfer information via RFID to a phone application, facilitating complete control and monitoring of results, from real-time data acquisition to measurement analysis and results presentation.

The project aims to reduce the average time to diagnosis of endometriosis from eight years to just a few days, which will revolutionise healthcare. This initiative will not only allow for early treatment, preventing the worsening of debilitating symptoms and optimising infertility care, but will also significantly improve the quality of life of patients.

Click here for the full article.